IL-13 receptor-directed cancer vaccines and immunotherapy

Immunotherapy

Volumn 4, Issue 4, 2012, Pages 443-451

  Nakashima, Hideyuki ^a   Husain, Syed R ^a   Puri, Raj K ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

combination therapy; DNA vaccine; IL 13 receptor 2; immunotoxin; myeloid derived suppressor cells

Indexed keywords

BUTYRIC ACID; CANCER VACCINE; COLECALCIFEROL; CXCL9 CHEMOKINE; DNA VACCINE; EPHRIN RECEPTOR A2; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GEMCITABINE; HLA A2 ANTIGEN; IMMUNOTOXIN; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN 13 RECEPTOR ALPHA2; INTERLEUKIN 4 RECEPTOR ALPHA; JANUS KINASE; SILDENAFIL; STAT PROTEIN; SURVIVIN; TRICHOSTATIN A; VORINOSTAT;

ANTIGEN SPECIFICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GLIOBLASTOMA; HEAD AND NECK CANCER; HISTONE MODIFICATION; HUMAN; KAPOSI SARCOMA; KIDNEY CANCER; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSION; IMMUNOTHERAPY; IMMUNOTOXINS; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; LYMPHOCYTE ACTIVATION; MICE; NEOPLASMS; VACCINES, DNA;

EID: 84860156472     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.28     Document Type: Review

References (79)

1. Berzofsky JA, Terabe M, Oh S et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. Clin. Investig. 113, 1515-1525 (2004). (Pubitemid 39071672)
2. Ribas A, Butterfeld LH, Glaspy JA, Economou JS. Current developments in cancer vaccines and cellular immunotherapy. J. Clin. Oncol. 21, 2415-2432 (2003). (Pubitemid 46621880)
3. Finn OJ. Cancer vaccines: between the idea and the reality. Nat. Rev. Immunol. 3, 630-641 (2003). (Pubitemid 37328666)
4. Romero P, Pittet M, Dutoit V et al. Therapeutic cancer vaccines based on molecularly defned human tumor antigens. Vaccine 20 (Suppl. 4), A2-A7 (2002). (Pubitemid 35449401)
5. Caput D, Laurent P, Kaghad M et al. Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor a chain. J. Biol. Chem. 271, 16921-16926 (1996). (Pubitemid 26239062)
6. Donaldson DD, Whitters MJ, Fitz LJ et al. The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1. J. Immunol. 161, 2317-2324 (1998). (Pubitemid 28397044)
7. David MD, Bertoglio J, Pierre J. Functional characterization of IL-13 receptor alpha2 gene promoter: a critical role of the transcription factor STAT6 for regulated expression. Oncogene 22, 3386-3394 (2003). (Pubitemid 36713735)
8. Husain SR, Puri RK. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. J. Neurooncol. 65, 37-48 (2003). (Pubitemid 37441313)
9. Joshi BH, Plautz GE, Puri RK. Interleukin-13 receptor alpha 2 chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res. 60, 116 8-1172 (2000).
10. Kawakami M, Kawakami K, Takahashi S, Abe M, Puri RK. Analysis of interleukin-13 receptor a2 expression in human pediatric brain tumors. Cancer 101, 1036-1042 (2004). (Pubitemid 39100438)
11. Kawakami M, Kawakami K, Kasperbauer JL et al. Interleukin-13 receptor alpha2 chain in human head and neck cancer serves as a unique diagnostic marker. Clin. Cancer Res. 9, 6381-6388 (2003). (Pubitemid 38031823)
12. Puri RK, Leland P, Obiri NI et al. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). Blood 8 7, 4333-4339 (1996). (Pubitemid 26155030)
13. Kawakami K, Puri RK. Interleukin-13 and cancer. In: Interleukin-13. Brombacher F (Ed.). Landes Bioscience, TX, USA 65-78 (2003).
14. Joshi BH, Kawakami K, Leland P, Puri RK. Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin. Clin. Cancer Res. 8, 1948-1956 (2002). (Pubitemid 34633758)
15. Kioi M, Kawakami M, Shimamura T, Husain SR, Puri RK. Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy. Cancer 107, 1407-1418 (2006). (Pubitemid 44452792)
16. Shimamura T, Fujisawa T, Husain SR, Joshi B, Puri RK. Interleukin 13 mediates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 Pseudomonas exotoxin in pancreatic cancer therapy. Clin. Cancer Res. 16, 577-586 (2010).
17. Lai EW, Joshi BH, Martiniova L et al. Overexpression of interleukin-13 receptor-alpha2 in neuroendocrine malignant pheochromocytoma: a novel target for receptor directed anti-cancer therapy. J. Clin. Endocrinol. Metab. 94, 2952-2957 (2009).
18. Joshi BH, Leland P, Calvo A, Green JE, Puri RK. Human adrenomedullin up-regulates interleukin-13 receptor alpha2 chain in prostate cancer in vitro and in vivo: a novel approach to sensitize prostate cancer to anticancer therapy. Cancer Res. 68, 9311-9317 (2008).
19. Husain SR, Obiri NI, Gill P et al. Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein. Clin. Cancer Res. 3, 151-156 (1997). (Pubitemid 27107288)
20. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13Ralpha2 receptor is involved in induction of TGF-beta1 production and fbrosis. Nat. Med. 12, 99-106 (2006). (Pubitemid 43050083)
21. Kawakami K, Taguchi J, Murata T, Puri RK. The interleukin-13 receptor a2 chain: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway. Blood 97, 2673-2679 (2001).
22. Chiaramonte MG, Mentink-Kane M, Jacobson BA et al. Regulation and function of the interleukin 13 receptor alpha 2 during a T helper cell type 2-dominant immune response. J. Exp. Med. 1 97, 687-701 (2003). (Pubitemid 36350864)
23. Rahaman SO, Sharma P, Harbor PC, Aman MJ, Vogelbaum MA, Haque SJ. IL-13R(alpha)2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells. Cancer Res. 62, 1103-1109 (2002). (Pubitemid 34160294)
24. Jakubzick C, Choi ES, Kunkel SL, Joshi BH, Puri RK, Hogaboam CM. Impact of interleukin-13 responsiveness on the synthetic and proliferative properties of Th1-and Th2-type pulmonary granuloma fbroblasts. Am. J. Pathol. 162, 1475-1486 (2003). (Pubitemid 36512829)
25. Yoshikawa M, Nakajima T, Tsukidate T et al. TNF-alpha and IL-4 regulate expression of IL-13 receptor alpha2 on human fbroblasts. Biochem. Biophys. Res. Commun. 312, 1248-1255 (2003). (Pubitemid 37490951)
26. Minn AJ, Gupta GP, Siegel PM et al. Genes that mediate breast cancer metastasis to lung. Nature 436, 518-524 (2005). (Pubitemid 41112921)
27. Fujisawa T, Joshi B, Nakajima A, Puri RK. A novel role of interleukin-13 receptor {alpha}2 in pancreatic cancer invasion and metastasis. Cancer Res. 69, 8678-8685 (2009).
28. Fujisawa T, Joshi BH, Puri RK. IL-13 regulates cancer invasion and metastasis through IL-13Ra2 via ERK/AP-1. Int. J. Cancer doi:10.1002/ijc.26366 (2011) (Epub ahead of print).
29. Tang DC, Devit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 356, 152-154 (1992).
30. Ulmer JB, Donnelly JJ, Parker SE et al. Heterologous protection against infuenza by injection of DNA encoding a viral protein. Science 259 (5102), 1745-1749 (1993). (Pubitemid 23114660)
31. Kawakami K, Terabe M, Kawakami M, Berzofsky JA, Puri RK. Characterization of a novel human tumor antigen interleukin-13 receptor alpha2 chain. Cancer Res. 66, 4434-4442 (2006).
32. Mintz A, Gibo DM, Madhankumar AB, Cladel NM, Christensen ND, Debinski W. Protein-and DNA-based active immunotherapy targeting interleukin-13 receptor alpha2. Cancer Biother. Radiopharm. 23, 581-589 (2008).
33. Emens LA, Jaffee EM. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res. 65, 8059-8064 (2005). (Pubitemid 41330564)
34. Gulley JL, Madan RA, Arlen PM. Enhancing effcacy of therapeutic vaccinations by combination with other modalities. Vaccine 25(Suppl. 2), B89-B96 (2007). (Pubitemid 47488548)
35. Nakashima H, Fujisawa T, Husain SR, Puri RK. Interleukin-13 receptor alpha2 DNA prime boost vaccine induces tumor immunity in murine tumor models. J. Transl Med. 8, 116 (2010).
36. Kunwar S, Chang S, Sampson J et al. Phase III randomized evaluation of CED of IL13-PE38QQR (CB) compared to gliadel wafers with survival endpoint in glioblastoma (GBM) patients at frst recurrence: report of the PRECISE study. Neuro-Oncology 12, 871-878(2010).
37. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin treatment of cancer. Annu. Rev. Med. 58, 221-237 (2007). (Pubitemid 46706511)
38. Nakashima H, Terabe M, Berzofsky JA, Husain SR, Puri RK. A novel combination immunotherapy for cancer by IL-13ra2-targeted DNA vaccine and immunotoxin in murine tumor models. J. Immunol. 187, 4935-4946 (2011).
39. Ostrand-Rosenberg S, Baskar S, Patterson N, Clements VK. Expression of MHC class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells. Tissue Antigens 47, 414-421 (1996). (Pubitemid 26168346)
40. Okano F, Storkus WJ, Chambers WH, Pollack IF, Okada H. Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clin. Cancer Res. 8, 2851-2855 (2002). (Pubitemid 35025729)
41. Eguchi J, Hatano M, Nishimura F et al. Identification of interleukin-13 receptor α2 peptide analogues capable of inducing improved antiglioma CTL responses. Cancer Res. 66, 5883-5891 (2006). (Pubitemid 43927143)
42. Ueda R, Low KL, Zhu X et al. Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma. J. Transl Med. 5, 68 (2007).
43. Okada H, Low KL, Kohanbash G, McDonald HA, Hamilton RL, Pollack IF. Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas. J. Neurooncol. 88, 245-250 (2008).
44. Shimato S, Natsume A, Wakabayashi T et al. Identification of a human leukocyte antigen-A24-restricted T-cell epitope derived from interleukin-13 receptor alpha2 chain, a glioma-associated antigen. J. Neurosurg. 109, 117-122 (2008). (Pubitemid 351930529)
45. Saka M, Amano T, Kajiwara K et al. Vacci ne therapy with dendritic cells transfected with IL13Ra2 mRNA for glioma in mice. J. Neurosurg. 113, 270-279 (2010).
46. Deangelis LM. Brain tumors. N. Eng. J. Med. 344(2), 114-123 (2001).
47. Buckner JC. Factors infuencing survival in high-grade gliomas. Semin. Oncol. 30(Suppl. 19), 10-14 (2003). (Pubitemid 38199157)
48. Hsi LC, Kundu S, Palomo J et al. Silencing IL-13R{alpha}2 promotes glioblastoma cell death via endogenous signaling. Mol. Cancer Ther. 10, 1149-116 0 (2 011).
49. + T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with a-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J. Clin. Oncol. 29, 330-336 (2011).
50. Cooper LJ, Kalos M, Digiusto D et al. T-c e l l genetic modification for re-directed tumor recognition. Cancer Chemother. Biol. Response Modif. 22, 293-324 (2005).
51. Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res. 64, 9160-9166 (20 04). (Pubitemid 39665531)
52. 18F-FHBG PET in a patient with glioma. Nat. Clin. Prac. Oncol. 6, 53-58 (2009).
53. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429, 457-463 (2004). (Pubitemid 38715140)
54. Takenouchi M, Hirai S, Sakuragi N, Yagita H, Hamada H, Kato K. Epigenetic modulation enhances the therapeutic effect of anti-IL-13Rα2 antibody in human mesothelioma xenografts. Clin. Cancer Res. 17, 2819-2829 (2011).
55. Fujisawa T, Joshi BH, Puri RK. Histone modification enhances the effectiveness of IL-13 receptor targeted immunotoxin in murine models of human pancreatic cancer. J. Transl Med. 9, 37 (2011).
56. Herber DL, Nagaraj S, Djeu JY, Gabrilovich DI. Mechanism and therapeutic reversal of immune suppression in cancer. Cancer Res. 67, 5067-5069 (2007). (Pubitemid 46997239)
57. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6, 295-307 (2006).
58. + suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2, 389-400 (2002). (Pubitemid 37328746)
59. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10, 942-949 (2004). (Pubitemid 39273735)
60. McHugh RS, Whitters MJ, Piccirillo CA et al. CD4+CD25+ immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 16, 311-323 (2002). (Pubitemid 34211969)
61. Stephens GL, McHugh RS, Whitters MJ et al. Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. J. Immunol. 173, 5008-5020 (2004). (Pubitemid 39387783)
62. Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat. Immunol. 8, 1353-1362 (2007). (Pubitemid 350131172)
63. + regulatory cells that control intestinal infammation. J. Exp. Med. 192, 295-302 (2000). (Pubitemid 30470312)
64. Frey AB. Myeloid suppressor cells regulate the adaptive immune response to cancer. J. Clin. Invest. 116, 2587-2590 (2006). (Pubitemid 44511621)
65. Zea AH, Rodriguez PC, Atkins MB et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 65, 3044-3048 (2005). (Pubitemid 40524582)
66. + T cells. J. Clin. Invest. 116, 2777-2790 (2006). (Pubitemid 44511641)
67. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162-174 (2009).
68. + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66, 1123-1131 (2006). (Pubitemid 43165981)
69. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin- cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 58, 49-59 (2009).
70. + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 11, 6713-6721 (2005). (Pubitemid 41339014)
71. Kusmartsev S, Cheng F, Yu B, Sotomayor E, Lush R, Gabrilovich D. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 63, 4441-4449 (2003). (Pubitemid 36951016)
72. Serafni P, Meckel K, Kelso M et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J. Exp. Methods 203(12), 2691-2702 (2006). (Pubitemid 44833345)
73. Meyer C, Sevko A, Ramacher M et al. Chronic infammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc. Natl Acad. Sci. USA 108, 17111-17116 (2011).
74. Fichtner-Feigl S, Terabe M, Kitani A et al. Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2. Cancer Res. 68, 3467-3475 (2008).
75. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163, 5211-5218 (1999).
76. Qin H, Cha SC, Neelapu SS et al. Vaccine site infammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity. Blood 114, 414 2-4149 (20 09).
77. Davidson EJ, Faulkner RL, Sehr P et al. Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). Vaccine 22, 2722-2729 (2004). (Pubitemid 38900647)
78. Lindsey KR, Gritz L, Sherry R et al. Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma. Clin. Cancer Res. 12, 2526-2537 (2006).
79. Perales MA, Yuan J, Powel S et al. Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma. Mol. Ther. 16, 2022-2029 (2008).